| Patients (number) | Patients (%) | CHT cycles (mean number ± SD) |
---|
CHT/BT Regimensa | 58 | 82 | 8.7 ± 5.3 |
Combination Therapy with Biologicals |
FOLFOX + VEGF-A mAb | 12 | 21.5 | 7.7 ± 1.4 |
FOLFIRI + EGFR mAb | 11 | 19.0 | 11.7 ± 4.3 |
FOLFIRI + VEGF-A mAb | 10 | 17.2 | 7.5 ± 3.3 |
FOLFIRI + FOLFOX + VEGF-A mAb | 7 | 12.0 | 13.0 ± 3.2 |
FOLFOX + EGFR mAb | 6 | 10.3 | 11.0 ± 2.3 |
XELOX + VEGF-A mAb | 4 | 6.9 | 8.5 ± 3.4 |
Combination Therapy without Biologicals |
FOLFOX | 4 | 6.9 | 5.0 ± 1.6 |
XELOX | 2 | 3.4 | 4.6 ± 1.2 |
FOLFIRI | 2 | 3.4 | 7.0 ± 6.0 |
Naïve for CHT | 13 | 18 | 0.0 |
Total Patients | 71 | | |
- FOLFOX: 5-fluorouracil/oxaliplatin; XELOX: capecitabine/oxaliplatin; FOLFIRI: 5-fluorouracil/irinotecan
- EGFR mAb Epidermal Growth Factor Receptor inhibitor monoclonal antibody
- VEGF-A mAb Vascular Endothelial Growth Factor A monoclonal antibody
- aNote:
- a) All CLM patients completed their last CHT cycle at least 6 weeks before the blood draws used for our experiments and before surgical procedures
- b) The table refers all therapies received by CLM patients before surgery
- c) More than 91% of all CLM patients received one line therapy and all other patients received two lines (1st and 2nd) combination therapy: 3 patients received 1st FOLFOX and 2nd FOLFIRI + VEGF-A; 1 patient received 1st FOLFIRI + VEGF-A and 2nd FOLFOX + VEGF-A, and 1 patient received 1st FOLFIRI + VEGF-A and 2nd FOLFOX